Thursday 7 May, 2026
Objectives: Can pharmacometric (PMX) modeling support individualized dose optimization in pediatric thyroid diseases, where inter-individual variability, developmental changes, and heterogeneous…
Read moreOral: Clinical Applications
These abstracts are expected to deal with applications of pharmacometrics whose aim is to improve individual patient treatment. They may include studies that have identified covariates that can be applied to calculate the dose, or even better, if the application was able to take patient response (concentration, biomarker) and further improve the individual dose. They can include simulation studies that explore how to improve patient treatment by dose individualization. The abstract must indicate an algorithm demonstrating how an individual patient dose is calculated.
Development of a neonatal plasma and cerebrospinal fluid (CSF) population PK model for fosfomycin.
Thursday 16 October, 2025
Objectives: Fosfomycin is a potential component of empiric antimicrobial treatment where resistance to ampicillin or cefotaxime/gentamicin (SOC) is high1. Fosfomycin…
Read moreThe broad use of pharmacometrics in patient care: the case of blood transfusion and perioperative management
Thursday 16 October, 2025
Introduction: Despite millions of surgical procedures are performed every year1, multiple areas of perioperative management lack quantitative tools to guide…
Read moreA hybrid machine learning/pharmacokinetic approach improves predictive performance in model-informed precision dosing
Thursday 16 October, 2025
Objectives: Model-informed precision dosing (MIPD) typically leverages empirical Bayes estimates of pharmacokinetic (PK) parameters, allowing for individualization of treatment at…
Read moreAssessment of a model to correlate early tumor size response to overall survival in relapsed or refractory diffuse large B cell lymphoma patients
Thursday 16 October, 2025
Objectives: To use tumor size metrics measured during treatment to predict overall survival (OS) in patients with relapsed or refractory…
Read moreSemi-mechanistic modeling of tumor size and overall survival including machine learning-derived tumor heterogeneity
Thursday 16 October, 2025
Objectives: Total tumor size (TS), expressed as the sum of longest diameters (SLD) of the individual tumor lesions (iTLs), is…
Read moreA semi-physiological framework to predict changes in pharmacokinetics of cytotoxic drugs in pregnant women
Thursday 16 October, 2025
Objectives: Physiological changes during pregnancy might have an influence on pharmacokinetics (PK) and hence on the efficacy and toxicity of…
Read moreA pharmacometric approach to optimise Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide for children with tuberculosis
Thursday 16 October, 2025
Objectives: While children contribute 11% of all tuberculosis (TB) cases globally, they account disproportionately for TB mortality (14%).1 Reports of low…
Read moreModel-based characterization of neutrophil dynamics in children receiving busulfan or treosulfan for hematopoietic stem cell transplant conditioning
Thursday 16 October, 2025
Objectives: Busulfan (Bu) and treosulfan (Treo) are used in the conditioning prior to paediatric haematopoietic stem cell transplantation (HSCT). Myeloid…
Read morePharmacokinetics During Hemodialysis and Hemodiafiltration: Dialysis Clearance is more important than Dialysis Efficiency – Application to Amikacin
Thursday 16 October, 2025
Objectives: Intermitted dialysis is the most common renal replacement therapy for patients with end stage renal disease. During hemodialysis (HD)…
Read more